Rajesh Jain has filed a regulatory disclosure with BSE Limited regarding his substantial acquisition of shares in Cian Healthcare Limited, completing the formal compliance requirements under SEBI Takeover Regulations. The disclosure, submitted on March 18, 2026, provides comprehensive details of his 52,50,000 equity share acquisition through an NCLT-approved resolution plan.

SEBI Regulatory Compliance

The acquisition triggered mandatory disclosure requirements under Regulation 10(6) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011. Rajesh Jain's filing with BSE Limited confirms his compliance with regulatory obligations following the share allotment completed on March 16, 2026.

Acquisition Structure and Details

The share acquisition was executed through preferential allotment pursuant to a resolution plan approved by the National Company Law Tribunal, Mumbai Bench, on December 18, 2025. Rajesh Jain acquired 52,50,000 fully paid-up equity shares at face value of INR 10.00 per share, totaling INR 5,25,00,000.

Consolidated Shareholding Pattern

Following the acquisition, the promoter group's consolidated holding has reached 95% of Cian Healthcare's total equity share capital. The group includes Rajesh Jain as the acquirer, along with persons acting in concert - Ananta Medicare Limited and Pradeep Kumar Jain.

Corporate Restructuring Impact

The acquisition represents a significant milestone in Cian Healthcare's corporate restructuring under the NCLT-approved resolution plan. The transaction benefits from exemption provisions under SEBI regulations, specifically Regulation 10(1)(da), which covers acquisitions made pursuant to approved resolution plans.

The filing confirms Cian Healthcare's listing status on BSE Limited and establishes the new ownership structure following the successful implementation of the resolution plan approved by the Mumbai Bench of the National Company Law Tribunal.

Cian Healthcare Limited announced key governance decisions following its Board of Directors meeting held on March 16, 2026. The physical meeting, which commenced at 02:00 P.M. (IST) and concluded at 03:38 P.M. (IST), addressed critical authorization matters and leadership appointments in compliance with SEBI regulations.

Authorization of Key Managerial Personnel

The Board approved granting authorization to Key Managerial Personnel for determining the materiality of company events and information. This authorization enables designated personnel to make timely disclosures to BSE Limited under Regulation 30(5) of the SEBI Listing Regulations, read with SEBI Master Circular No. HO/49/14/14(7)2025-CFDPOD2/1/3762/2026 dated January 30, 2026.

This authorization framework ensures compliance with disclosure requirements while enabling efficient decision-making processes for material event reporting to stock exchanges.

New Chairperson Appointment

The Board designated Mr. Manish Goswami as the new Chairperson of the Board, effective March 16, 2026. Mr. Goswami, who serves as an Independent Non-Executive Director, will hold the Chairperson position for a tenure of 1 year. The appointment was made based on the recommendation of the company's Nomination and Remuneration Committee.

Regulatory Compliance

The decisions were made in compliance with Regulation 30 read with Schedule III of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015. The company filed the disclosure with BSE Limited under scrip code 542678 and trading symbol CHCL, ensuring transparency with stakeholders and regulatory authorities.

The meeting outcome reflects Cian Healthcare Limited's commitment to maintaining robust governance structures while ensuring compliance with evolving regulatory requirements in the healthcare sector.